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Aberrations in the methylation status of noncoding genomic repeat DNA sequences and specific gene
promoter region are important epigenetic events in melanoma progression. Promoter methylation status in
long interspersed nucleotide element-1 (LINE-1) and absent in melanoma-1 (AIM1; 6q21) associated with
melanoma progression and disease outcome was assessed. LINE-1 and AIM1 methylation status was assessed in
paraffin-embedded archival tissue (PEAT; n¼ 133) and in melanoma patients’ serum (n¼ 56). LINE-1 U-Index
(hypomethylation) and AIM1 were analyzed in microdissected melanoma PEAT sections. The LINE-1 U-Index of
melanoma (n¼ 100) was significantly higher than that of normal skin (n¼ 14) and nevi (n¼ 12; P¼ 0.0004). LINE-1
U-Index level was elevated with increasing American Joint Committee on Cancer (AJCC) stage (Po0.0001). AIM1
promoter hypermethylation was found in higher frequency (P¼ 0.005) in metastatic melanoma (65%) than in
primary melanomas (38%). When analyzed, high LINE-1 U-Index and/or AIM1 methylation in melanomas were
associated with disease-free survival (DFS) and overall survival (OS) in stage I/II patients (P¼ 0.017 and 0.027,
respectively). In multivariate analysis, melanoma AIM1 methylation status was a significant prognostic factor of
OS (P¼ 0.032). Furthermore, serum unmethylated LINE-1 was at higher levels in both stage III (n¼ 20) and stage
IV (n¼ 36) patients compared with healthy donors (n¼ 14; P¼ 0.022). Circulating methylated AIM1 was detected
in patients’ serum and was predictive of OS in stage IV patients (P¼ 0.009). LINE-1 hypomethylation and AIM1
hypermethylation have prognostic utility in both melanoma patients’ tumors and serum.
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INTRODUCTION
Epigenetic studies have shown that the methylation status of
CpG islands in the promoter region of tumor-related genes, as
well as noncoding repeat genomic sequences, are associated
with progression of cancers (Tanemura et al., 2009; van
Hoesel et al., 2011). The former has been linked to
transcriptional silencing (Jones and Baylin, 2007), but the
latter is poorly understood in cancer progression (Eden et al.,
2003; Gaudet et al., 2003; de Maat et al., 2010a, 2010b;
Sunami et al., 2011).
Long interspersed nucleotide elements (LINEs) represent a
noncoding repeat sequence in humans. They are 6–8 kb long,
GC-poor sequences with open reading frames 1 and 2,
encode a reverse transcriptase and endonuclease, and make
up B17% of the human genome (Lander et al., 2001;
Ostertag and Kazazian, 2001; Ovchinnikov et al., 2002). The
genome containsB5,000 full-length 6.0 kb LINE-1 elements,
60–100 of which are still capable of retrotransposition (Scott
et al., 1987; Minakami et al., 1992; Brouha et al., 2003).
LINE-1 is hypermethylated in normal cells and hypomethyl-
ated in several malignancies (Yang et al., 2004; Estecio et al.,
2007; Sunami et al., 2009). LINE-1 hypomethylation level in
tumor has been correlated to tumor progression (Chalitch-
agorn et al., 2004; Cho et al., 2007; Ogino et al., 2008a;
Pattamadilok et al., 2008; Daskalos et al., 2009; Lee et al.,
2009; Tellez et al., 2009). The association of LINE-1
hypomethylation status has been assessed in human cuta-
neous melanoma cell lines (Tellez et al., 2009), and the
activation of LINE-1 transcript has also been observed in
metastatic melanomas compared with primary melanomas
(Haqq et al., 2005). In this study, we assessed melanoma
tumor cells microdissected from paraffin-embedded archival
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tissue (PEAT) at different stages of primary and metastatic
melanoma to investigate LINE-1 methylation status during
tumor progression.
Methylation profiling of melanoma has demonstrated
inactivation of tumor-related genes by hypermethylation of
CpG islands in the promoter region (Furuta et al., 2004; Hoon
et al., 2004; Worm et al., 2004; Mirmohammadsadegh et al.,
2006; Patino and Susa, 2008; Tanemura et al., 2009). These
epigenetic changes are significant factors in melanoma
progression as we have recently shown (Tanemura et al.,
2009). A multidomain non-lens member of bg-crystallin
superfamily, with six structural domains formed from 12
bg–crystallin motifs, Absent in melanoma-1 (AIM1), not to be
confused with SLC45A2 (melanoma antigen Aim1) on
chromosome 5p13.2., was originally identified as a candidate
tumor-suppressor gene (chromosome 6q21; Ray et al., 1997;
Aravind et al., 2008). However, few studies have been
carried out on AIM1 in melanoma since then.
Higher prevalence of LINE-1 and tumor-suppressor genes
silenced by epigenetic aberration have been found on
chromosome 6 (Mungall et al., 2003) where AIM1 is also
located. Previous studies have demonstrated a correlation
between LINE-1 hypomethylation and CpG island hyper-
methylation of tumor-suppressor genes (Estecio et al., 2010;
Poage et al., 2011). As the genetic locus of AIM1 is proximal
to the binding site of several known transcription factors,
LINE-1 and AIM1 methylation status may be associated.
Studies have shown that epigenetic tumor tissue biomark-
ers can have utility as biomarkers for cell-free circulating
DNA (cf-cDNA; Schwarzenbach et al., 2011). Specific cf-
cDNAs have demonstrated prognostic utility in melanoma
patients (Mori et al., 2005). In this study, we assessed the level
of circulating unmethylated LINE-1 and methylated AIM1
DNA in the serum of patients with melanoma metastasis. We
demonstrated prognostic utility of unmethylated LINE-1 and
AIM1methylation in both melanoma tissues and serum. These
studies demonstrate that epigenetic aberrations of both coding
and noncoding regions can have potential utility as biomark-
ers in the tumors and serum of melanoma patients.
RESULTS
LINE-1 hypomethylation in melanomas
Using absolute quantitative assessment of methylated alleles
(AQAMA), microdissected melanoma cells were assessed for
their LINE-1 U-Index, which is calculated by dividing the
copy number of unmethylated templates by the total of both
unmethylated and methylated templates. The average LINE-1
U-Index of five melanoma cell lines was 0.79, whereas for
normal peripheral blood lymphocyte (PBL) DNA, the LINE-1
U-Index ranged from o0.1 to 0.2, similar to normal skin
and nevi. The LINE-1 U-Index of melanomas, including
both primary and metastatic tissues (n¼ 100, mean±SD;
0.32±0.26), was significantly higher than that of normal
skin (n¼14) and nevi (n¼ 12; mean±SD; 0.14±0.07; t-test;
P¼0.0004; Figure 1a). The LINE-1 U-Index level of meta-
static melanomas (American Joint Committee on Cancer
(AJCC) stages IIIm and IV: n¼ 56, mean±SD; 0.40±0.30)
was significantly higher than that of normal skin/nevi or
primary melanomas (AJCC stages Ip, IIp, and IIIp: n¼44,
mean±SD; 0.22±0.14; Tukey’s HSD (honest significance
test) Po0.0001 and P¼0.0001, respectively; Figure 1b).
Furthermore, LINE-1 U-Index in melanomas showed a
significant elevation with increasing stage of disease
(mean±SD; I: 0.20±0.05, II: 0.24±0.11, IIIp: 0.23±0.19,
IIIm: 0.27±0.23, and IV: 0.50±0.31, respectively; analysis
of variance Po0.0001; Figure 1c). Most notably, LINE-1 U-
Index level of stage IV melanomas (mean±SD; 0.50±0.31)
was significantly higher than that of other stages (New-
man–Keuls test, Po0.05). LINE-1 U-Index was not correlated
with patient age or other histopathological factors, including
tumor thickness, ulceration, or mitotic index.
LINE-1 U-Index was further compared in 13 autologous
pairs of primary (2 stage II and 11 stage IIIp) and metastatic
(9 stage IIIm and 4 stage IVm) tumors from 13 patients. In 11
pairs, LINE-1 U-Index values were higher in metastatic than
in respective paired primary tumors (Figure 1d). Signed-rank
test for the difference of LINE-1 U-Index between primary and
metastasis was significant (mean±SD; primary: 0.08±0.11,
metastasis: 0.20±0.22, P¼ 0.024). These results suggested
that hypomethylation of LINE-1 was a progressive factor in
melanomas.
AIM1 promoter methylation status in melanoma cell lines
Unlike LINE-1, AIM1 is a protein-encoding gene; therefore,
the evaluation of promoter methylation should cover regions
or CpG sites relevant to the downstream expression level.
Four melanoma lines (M-15, M-24, M-101, and LF-0023) and
normal PBL were subjected to matrix-assisted laser desorp-
tion/ionization time-of-flight mass spectrometry quantita-
tive analysis of the entire AIM1 promoter region to profile
CpG-site methylation status. CpG sites of M-15 and M-101
were highly methylated across the whole promoter region
compared with M-24, LF-0023, and normal PBL (Figure 2a).
The transcription of AIM1 was analyzed by reverse tran-
scriptase–PCR in the same melanoma lines (Figure 2b). AIM1
mRNA was not detected in the two highly AIM1 methylated
melanoma lines (M-15 and M-101). The two AIM1 unmethyl-
ated melanoma lines (M-24 and LF-0023) and normal PBL
showed high expression of AIM1. Specific CpG sites, most of
them related to mRNA transcription activity (Figure 2c), were
identified for methylation-specific PCR (MSP) study in PEAT
and cf-cDNA. The average percentage of methylation in the
selected region (CpG8–11) in M-15 (77%) and M-101 (81%)
was higher than those of the two AIM1 mRNA–positive cell
lines, M-24 and LF-0023, and donor PBL (o12%).
AIM1 expression was significantly increased in the two
methylated lines after treatment with 5-aza-20 deoxycytidine
(5Aza-dC; Supplementary Figure S1 online). This demon-
strated that demethylation of AIM1 promoter region can
reactivate AIM1 mRNA expression, suggesting that promoter
region methylation regulates AIM1 expression.
AIM1 methylation status and mRNA expression in PEAT
To evaluate the AIM1 methylation status in melanoma
tissues, we designed MSP primers to the specific CpG sites
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(CpG8–11) that were related to transcription levels of AIM1.
The AIM1 promoter was found hypermethylated in 57 of 112
(51%) melanoma tissues, as compared with none in
histopathologically normal skin (n¼ 14) and nevus tissues
(n¼12; Po0.0001). AIM1 promoter hypermethylation was
identified in 35 of 54 (65%) metastatic melanomas, as
compared with 22 of 58 (38%) primary melanomas
(P¼0.005); the frequency of hypermethylation progressively
increased with stage (Table 1).
AIM1 mRNA expression was assessed in four hypomethyl-
ated stage I melanoma primary tumors and in five hyper-
methylated stage IV metastatic tumors. AIM1 mRNA was
found in all four hypomethylated melanomas but showed
limited expression in the five hypermethylated melanomas
(Supplementary Figure S2 online).
Survival analyses of LINE-1 and AIM1 methylation status
We next evaluated the PEAT AIM1 and LINE-1 methylation as
biomarkers for prognostic significance. In early-stage primary
melanoma patients (n¼23), stepwise multivariate Cox
regression (variables age, gender, ulceration, Breslow,
primary site) demonstrated that AIM1 hypermethylation was
a significant prognostic predictor of overall survival (OS) in
stage I/II patients when age was included in the model
(P¼0.032, hazard ratio: 22.62, 95% confidence interval:
1.30–392.24). LINE-1, however, did not reach significance as
an individual biomarker. Univariate analysis of AIM1 or
LINE-1 alone showed no significance in prediction of OS or
disease-free survival (DFS). The relatively small sample size
of the survival analysis cohort may have contributed to the
differences in our survival cohort between univariate and
multivariate survival analysis results. In combination, patients
were categorized into two groups: patients who had presence
of either hypermethylated AIM1 or hypomethylated LINE-1,
and patients who did not have either event. The presence of
either hypermethylated AIM1 or hypomethylated LINE-1
correlated with significantly poorer patient OS and DFS in
univariate analysis of stage I/II melanoma (P¼ 0.027 and
0.017, respectively; Figure 3a and b). In multivariate analysis,
the combination was a significant prognostic predictor of
both OS and DFS in stage I/II patients (OS: P¼0.028, hazard
ratio: 6.46, 95% confidence interval: 1.22–34.15; DFS:
P¼0.046, hazard ratio: 8.65, 95% confidence interval:
1.04–72.06). Table 2 lists the clinicopathological factors for
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Figure 1. LINE-1 hypomethylation in paraffin-embedded archival tissues. Individual and mean (solid horizontal line) long interspersed nucleotide element-1
(LINE-1) U-Index values for tissue specimens of (a) normal skin versus primary/metastatic melanoma, (b) normal skin versus primary melanoma versus metastatic
melanoma and according to the (c) American Joint Committee on Cancer (AJCC) stage and (d) primary and metastatic paired samples. P-values were obtained by
(a, d) Student’s t-test, (b) Tukey’s HSD (honest significance test), and (c) analysis of variance (ANOVA). NS, not significant; U, unmethylated.
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patients included in survival analysis along with biomarker
prediction of OS results from the Cox regression model.
Serum cf-cDNA
To determine whether LINE-1 and/or AIM1 could be used for
prognostic assessment of serum (Mori et al., 2005), we
examined levels of circulating unmethylated LINE-1 and
methylated AIM1 in stage III and IV melanoma patients.
Patient serum samples had significantly higher unmethylated
LINE-1 than healthy donor serum (t-test; P¼ 0.022; Supple-
mentary Figure S3 online), and none of the normal healthy
donor serum samples had detectable unmethylated LINE-1
before 25 PCR cycles. The serum MSP assay detected
circulating AIM1 methylated DNA in 15% (3 of 20) of stage
III patients and 22% (8 of 36) of stage IV patients.
Unmethylated LINE-1 status in patients’ serum was limited
in prognostic utility in this set of patients. However, serum
methylated AIM1 DNA was correlated with OS in stage IV
patients (P¼ 0.0085, log-rank; Figure 4a) and not associated
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Figure 2. AIM1 (absent in melanoma-1) promoter methylation and gene expression. (a) CpG methylation in the promoter region of AIM1 gene as assessed
by PCR of three amplicons (A, B, and C) covering over 1,000 bp of the promoter region. (b) AIM1 mRNA expression in melanoma cell lines. GAPDH,
glyceraldehyde-3-phosphate dehydrogenase; PBL, peripheral blood lymphocyte. (c) Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF)
MassARRAY analysis of specific CpG sites as target region of methylation-specific PCR (MSP) primers for AIM1.
Table 1. Methylation status of AIM1 promoter region
in melanoma tissue
AJCC stage Hypermethylation
Normal tissue, total (n=26) 0 (0%)
Skin (n=14) 0 (0%)
Nevi (n=12) 0 (0%)
Primary melanoma, total (n=58) 22 (38%)
Stage I (n=14) 4 (29%)
Stage II (n=14) 8 (57%)
Stage III primary tumor (n=30) 10 (33%)
Metastasis tumor, total (n=54) 35 (65%)
Stage III nodal metastasis (n=23) 11 (48%)
Stage IV (n=31) 24 (77%)
Abbreviations: AIM1, absent in melanoma-1; AJCC, American Joint
Committee on Cancer.
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with the M stage. Patients found to have either serum
unmethylated LINE-1 or methylated AIM1 DNA have worse
prognosis compared with patients with neither (P¼0.0009,
log-rank; Figure 4b).
DISCUSSION
The progressive demethylation of LINE-1 in malignancies has
been correlated with increased aberrant genomic and
epigenomic events (Sunami et al., 2011). We demonstrated
that LINE-1 became progressively hypomethylated during
melanoma progression. LINE-1 hypomethylation level was
higher in stage IV melanomas compared with other stages.
These results suggested that LINE-1 hypomethylation may be
a significant factor in melanoma progression. Sigalotti et al.
(2011) previously demonstrated within stage IIIC melanomas
that higher methylation percentage of LINE-1 is correlated
with worse OS; in this study, we however, demonstrated
increasing hypomethylation of LINE-1 in advancing stages of
melanomas and in metastasis of autologous primary paired
tissues. The observation of LINE-1 hypomethylation during
tumor progression is in accordance with that found in
gastrointestinal cancers (Ogino et al., 2008a, b; Sunami
et al., 2011). These LINE-1 hypomethylation findings support
the pattern of genomic instability occurring during melanoma
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Figure 3. Kaplan–Meier survival curves for melanoma patients using a
combination of long interspersed nucleotide element-1 (LINE-1) and
absent in melanoma-1 (AIM1) methylation status in paraffin-embedded
archival tissue (PEAT). (a) Overall survival (OS) of patients with LINE-1
hypomethylation and/or AIM1 hypermethylation versus LINE-1
hypermethylation and AIM1 hypomethylation. M, hypermethylated; U,
hypomethylated. (b) Disease-free survival (DFS) of stage I and II melanoma
patients with LINE-1 hypomethylation and/or AIM1 hypermethylation versus
LINE-1 hypermethylation and AIM1 hypomethylation.
Table 2. Clinicopathological factors of AIM1/LINE-1
survival analysis set (n=72)
Clinicopathological factors
Stage I/II
(n=23) Cox OS
Stage III
(n=26)
Stage IV
(n=23)
Gender NS
Male 12 15 15
Female 11 11 8
Age (years) P=0.0203,
HR: 1.15,
Mean (SD) 68.4
(±8.9)
95% CI
(1.02–1.30)
62.4
(±17.1)
59.5
(±14.7)
Primary site NS
Extremities 12
Head/neck 6
Trunk 5
No. of distant sites
1 3
2 8
3+ 12
Breslow thickness NS
p1.00mm 8 3
1.01–2.00mm 6 5
2.01–4.00mm 6 8
44.00mm 1 10
Unknown 2 0
Ulceration NS
Present 7 13
Absent 13 11
Unknown 3 2
Mitotic index NS
High X11/mm2 2
Intermediate 5–10/mm2 1
Low p4/mm2 17
Unknown 3
No. of lymph nodes (+)
1 7
2–3 13
4+ 1
0 (Skin Met) 2
Unknown 3
LINE-1 or AIM1 P=0.0282,
HR: 6.46,
LINE-1/AIM1 11 95% CI
(1.22–34.15)
12 22
Neither 12 14 1
Abbreviations: AIM1, absent in melanoma-1; CI, confidence interval; HR,
hazard ratio; LINE-1, long interspersed nucleotide element-1; NS, not
significant; OS, overall survival.
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progression (Fujiwara et al., 1999). LINE-1 hypomethylation
has been suggested to facilitate genomic instability in cancer
cells (Sunami et al., 2011), and may have a role in the
activation of LINE-1 transcription in metastatic melanoma
(Haqq et al., 2005).
Chromosome 6q21-22 has been long presumed as a tumor-
suppressor region in melanoma, and several candidate tumor-
suppressor genes located at 6q21-23 have been proposed.
Trent et al. (1990) demonstrated that melanoma lines directly
introduced with a normal copy of chromosome 6 lost their
ability to form tumors in nude mice, and the loss of
chromosome 6 from melanoma microcell hybrids resulted in
reversion to tumorigenicity of these cells. High frequency of
loss of heterozygosity of chromosome 6q has also been
reported in melanoma lines and tissues (Fujiwara et al., 1999;
Bahrami et al., 2007; Stark and Hayward, 2007). However, it
still remains unclear which key genes are specifically involved
in melanoma progression in the 6q21-22 region of melano-
mas. Recently, lower levels of AIM1 expression was shown to
be correlated with 6q21 deletion, and promoter hypermeth-
ylation of AIM1 downregulated AIM1 expression in natural
killer–cell malignancies (Iqbal et al., 2009). We found AIM1 to
be significantly suppressed during melanoma progression.
Our study showed a significant association between
LINE-1 hypomethylation or AIM1 hypermethylation and
poorer survival. The combination analysis of LINE-1 (U) and/
or AIM1 (M) in melanomas was a significant predictor for OS
and DFS, suggesting that the combination analysis of LINE-1
hypomethylation and AIM1 hypermethylation can improve
their sensitivity as prognostic biomarkers. Studies have
demonstrated that genomic methylation status is dynamic
during tumor progression (Tanemura et al., 2009) where
genomic repeats and specific gene promoter region can,
independently or concurrently, become aberrantly meth-
ylated during tumor progression (de Maat et al., 2007b,
2008).
cf-cDNA has been shown as a promising clinical
biomarker for various malignancies (Mori et al., 2005;
Umetani et al., 2006; Schwarzenbach et al., 2011). We have
reported the prognostic utility of specific circulating methy-
lated DNA, RASSF1A, and RAR-b2 in stage IV melanoma
patients (Mori et al., 2005). Although serum unmethylated
LINE-1 was higher in advanced melanoma patients, it was not
correlated with disease outcome. A larger defined cohort of
patients may be needed to demonstrate its potential
prognostic utility. Patients with circulating methylated AIM1
DNA, on the other hand, had worse OS than those who did
not. The combination of AIM1 or LINE-1 cf-cDNA was
significantly correlated with OS. The analysis indicated that
both unmethylated and methylated cf-cDNAs can be used for
prognostic utility.
In conclusion, we demonstrated that LINE-1 hypomethyla-
tion and AIM1 hypermethylation status are related to tumor
progression. Together, these two factors have prognostic
value as shown with detection of cf-cDNA in melanoma
patients’ serum for predicting outcome in tissue and in
detecting serum cf-cDNA for real-time disease status.
MATERIALS AND METHODS
Specimens
Melanoma patients treated at Saint John’s Health Center between
1993 and 2008 were reviewed for inclusion in this study. PEAT
melanomas from the patients were obtained under an institutional
review board protocol that was approved by the Saint John’s Health
Center/John Wayne Cancer Institute joint institutional review board
and Western institutional review board.
The LINE-1 study included 126 PEAT specimens (113 patients).
Among these were 13 pairs of autologous tissues from a primary
tumor and its synchronous regional metastasis (5 pairs) or
metachronous regional/distant metastasis (8 pairs). Of the remaining
100 specimens, 44 were from the primary tumors of patients with
AJCC melanoma stage I (n¼ 13), stage II (n¼ 11), or stage III (n¼ 20);
56 were from metastases of patients with stage III (n¼ 23) or stage IV
(n¼ 33).
The AIM1 study included 112 PEAT specimens from 92 patients
with AJCC stage I (n¼ 14), stage II (n¼ 14), stage III (n¼ 30 primaries
and 23 lymph node metastases), and stage IV (n¼ 31 distant
metastases) melanoma. A total of 72 patients from the AIM1 study
overlapped with the LINE-1 study, with AJCC stage I (n¼ 13), stage II
(n¼ 10), stage III (n¼ 15 primary tumors and 11 lymph node
metastases), and stage IV (n¼ 23 distant metastases) melanoma. In
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Figure 4. Kaplan–Meier survival curves for stage IV patients in serum
studies. (a) Overall survival (OS) of stage IV patients with methylated- versus
unmethylated-AIM1 (absent in melanoma-1) circulating cell-free DNA (cf-
cDNA). (b) OS of stage IV patients with LINE-1 (long interspersed nucleotide
element-1) unmethylated and/or AIM1 methylated cf-cDNA versus those with
LINE-1 methylated and AIM1 unmethylated cf-cDNA. M, methylated; U,
unmethylated.
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all, 26 negative controls were obtained from histopathologically
negative normal skin (n¼ 14) and nevi tissue (n¼ 12).
Serum from 56 AJCC stage III (n¼ 20) and IV (n¼ 36) melanoma
patients and 14 healthy donors with serum separator tubes was
filtered and cryopreserved at 80 1C (Mori et al., 2005; Koyanagi
et al., 2010). The sera from all the patients were obtained after
informed consent.
Melanoma cell lines and treatment
Melanoma cell lines (M-12, M-15, M-24, M-101, and LF-0023)
established from metastatic tumors at John Wayne Cancer Institute
were cultured and harvested for the study and as assay controls. The
melanoma lines were cultured as previously described (Narita et al.,
2009). Three melanoma cell lines, M-15, M-101, and M-24, were
treated with 5Aza-dC (Sigma-Aldrich, St Louis, MO) for AIM1
reactivation. Melanoma cells were cultured and then treated with
culture medium containing 5 mM 5Aza-dC or DMSO as a vehicle
control. 5Aza-dC-containing medium was administered daily, and
the cells were collected for assessment after 48 hours.
DNA isolation from PEAT and serum samples
Tissue sections were cut for hematoxylin and eosin and micro-
dissected (de Maat et al., 2007b, 2010a). Microdissected tissues
were incubated at 50 1C overnight in lysis buffer (50mM Tris, 1mM
EDTA, 2.5% Tween 20, 6.0mAU proteinase K) followed by
incubation at 95 1C (10minutes). DNA was extracted by phenol–-
chloroform–isoamyl extraction and ethanol precipitation. DNA
concentration was determined by both spectrophotometer reading
at 260/280 nm and Quant-iT PicoGreen dsDNA assay kit (Invitrogen,
Carlsbad, CA).
Serum samples (500 ml) were diluted with 0.9% NaCl and mixed
with a premix consisting of proteinase K and 10% SDS. Samples
were incubated at 50 1C (3 hours). After incubation, phenol–chloro-
form–isoamyl (25:24:1, pH 8.0; Sigma-Aldrich) was added to each
sample. DNA was extracted and quantified; up to 300 ng of DNA
was subjected to sodium bisulfite modification using EpiTect
bisulfite kit (Qiagen, Valencia, CA; de Maat et al., 2010b).
AQAMA
We previously reported accurate, targeted methylation analysis of
PEAT using AQAMA, an assay based on bisulfite modification of
DNA and real-time PCR using two hydrolysis minor groove binder
probes specific for the methylated or unmethylated templates
labeled with fluorophores (de Maat et al., 2007a; Tanemura et al.,
2009). Assays were carried out in triplicate and the average copy
number was used. LINE-1 hypomethylated melanoma line DNA and
LINE-1 methylated PBL of healthy donors were included as controls.
The LINE-1 hypomethylation level was a continuous variable
defined as the copy number of unmethylated LINE-1(U) relative to
the total LINE-1 copy number, which is the sum of the copy number
of methylated LINE-1(M) and U(U/[UþM]), hereafter referred to as
LINE-1 U-Index. The LINE-1 U-Index of each sample was compared
for hypomethylation status. For assessment of cf-cDNA, modifica-
tions of the assay included the use of 4 ml of bisulfite-treated DNA as
template and PerfeCTa qPCR Supermix (Quanta BioSciences,
Gaithersburg, MD). For serum, qPCR quantification cycle (Cq) cutoff
at 25 was used to qualify whether there is sufficient level of unmethylated
LINE-1 DNA present above that of a healthy donor serum.
RNA isolation and reverse transcriptase–PCR
Total RNA from cultured cells was extracted using TRI-Reagent
(Molecular Research Center, Cincinnati, OH). For melanomas,
5 10-mm sections were cut from PEAT blocks on a microtome.
Apart from deparaffinization, RNA was extracted from PEAT using
RNAwiz (Ambion, Austin, TX) after proteinase K digestion as
previously described (Takeuchi et al., 2004; Koyanagi et al.,
2006b). RNA quantity and quality were accessed by spectro-
photometry and Quant-iT RiboGreen RNA assay (Invitrogen).
Reverse transcription of total RNA (1mg) and PCR with 5ml of
complementary DNA was performed as previously described
(Koyanagi et al., 2006a). AIM1-specific primers are 50-TTAGTTTTA
GACATTAAAGGGGG-30 and 50-TGGAAGGACCTCCAGAAGAT-30.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was assessed
by reverse transcriptase–PCR as reference and for normalization.
Specimens were amplified with a pre-cycling hold at 95 1C
(10minutes), followed by 25 cycles of 95 1C, 55 1C for GAPDH/
58 1C for AIM1, and 72 1C (1minute).
Matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry
EpiTYPER assay (Sequenom, San Diego, CA) is a tool used for the
detection and quantification of DNA methylation using matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry
and MassCLEAVE analysis based on a base-specific cleavage
reaction (Radpour et al., 2008). This assay enables accurate
quantification of DNA methylation (Coolen et al., 2007). Each
CpG site within an amplicon is assessed for its methylation status.
Three pairs of primers were designed to cover the promoter region of
AIM1 as predicted by Promoter Scan Web (http://www-bimas.cit.
nih.gov/molbio/proscan/) using EpiDesigner (Sequenom; Supple-
mentary Figure S4 online). Bisulfite-treated DNA PCR amplification
was performed with a pre-cycling hold at 94 1C (15minutes)
followed by 45 cycles of 94 1C (20 seconds), 58 1C (30 seconds),
and at 72 1C (1minute) and a final extension at 72 1C (2minutes).
Post-PCR amplicons were assessed as previously reported using
MassARRAY (Yoshimura et al., 2011).
MSP
Bisulfite conversion–based PCR primers were designed to cover the
region where methylation percentage was well correlated with
mRNA expression. For MSP on PEAT, the forward and reverse
methylation-specific primers were 50-D4-TTTGTTTTTTCGTTTTT
TTAGGTTC-30 and 50-ACTAACATCCAATACCCGCG-30, respec-
tively. Forward and reverse unmethylation-specific primers were
50-D3-TGTTTTTTTGTTTTTTTAGGTTTGT-30 and 50-ACTAACATCC
AATACCCACAC-30, respectively. For serum DNA MSP, different
reverse primers were selected to reduce product size for optimal
detection: methylation, 50-CGCGATAACGCTCCG-30 and unmeth-
ylation, 50-CAATAAACACAATAACACTCCA-30.
For PEAT, PCR was performed with Accustart Taq DNA
polymerase (0.5U) (Quanta BioSciences), 1 PCR buffer, 4.5mM
MgCl2, 0.2 mmol l
–1 each of forward and reverse primer, 800 mmol l–1
deoxynucleotide triphosphates, and 1 ml bisulfite-treated DNA.
Amplifications were carried out at 95 1C (3minutes) followed by
40 cycles of 95, 61, and 72 1C (30 seconds) for both methylated and
unmethylated reactions, and a final extension at 72 1C (7minutes).
For circulating AIM1 DNA in serum, 3 ml of bisulfite-treated DNA
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was used as template in the PCR reaction, and PerfeCTa qPCR
Supermix was used in place of Accustart Taq DNA polymerase
cocktail. Amplifications were carried out at 95 1C (3minutes)
followed by 40 cycles of 95, 59, and 72 1C (30 seconds). PCR
products were analyzed by capillary array electrophoresis (Beckman
Coulter CEQ 8000X; Beckman Coulter, Brea, CA) as previously
reported (Tanemura et al., 2009). Methylation assay control includes
PBL DNA methylated in vitro with excess SssI methyltransferase
(New England BioLabs, Ipswich, MA; Umetani et al., 2005).
Unmethylated assay control includes leukocyte DNA that was
amplified by phi-29 DNA polymerase to produce universally
unmethylated control.
Biostatistical analysis
All data were analyzed using SAS software (version 9.1.3, SAS
Institute, Cary, NC). The w2 test or Fisher’s exact test was used to
analyze categorical variables. Analysis of variance, Student’s t-test,
Kruskal–Wallis, or Tukey’s HSD tests were used to compare
independent continuous variables across different strata. The Cochran
–Armitage trend test analyzed LINE-1 hypomethylation across AJCC
stages. LINE-1 U-indexes were compared at each AJCC stage using the
Student–Newman–Keuls test. Signed-rank test and McNemar’s test
were used to compare LINE-1 U-Index in primary and metastatic
paired tissues. Correlation between LINE-1 U-Index and patients’ age
was analyzed using Spearman’s rank test correlation efficient.
Association between methylation status of AIM1 and AJCC stage
was assessed by the w2 test, whereas trend analysis was conducted
using the Cochran–Armitage trend test. Cox proportional hazards
regression models for OS and DFS were built incorporating
methylation status of LINE-1 and AIM1 along with other clinical
variables such as Breslow, age, gender, and number of metastases. To
convert LINE-1 U-Index into a categorical value for analysis, a cutoff
of 0.297 was established using the average of LINE-1 U-Indexes from
normal skin samples plus 2 SD. A sample with LINE-1 U-Index
X0.297 was considered hypomethylated in LINE-1. When combining
both AIM1 and LINE-1 status, patients with either AIM1 hypermeth-
ylation or LINE-1 hypomethylation were compared with patients who
had neither event. The proportional hazards assumption was tested in
building the Cox proportional hazards regression model. Survival
curves were generated using the Kaplan–Meier method. A P-value of
o0.05 was considered statistically significant. These analyses were
performed in compliance with REMARK (McShane et al., 2005).
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
We thank Gwen Berry and Kana Sato for editorial support, and Nicholas
Donovan and the Department of Molecular Oncology for their technical
support. This work was supported by the Dr Miriam and Sheldon G. Adelson
Medical Research Foundation, Ruth and Martin H. Weil Fund, Melanoma
Research Alliance, and award numbers P0 CA029605 and P0 CA012582 from
the National Institutes of Health, National Cancer Institute. The content is solely
the responsibility of the authors and does not necessarily represent the official
view of the National Cancer Institute or the National Institutes of Health.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper at http://
www.nature.com/jid
REFERENCES
Aravind P, Wistow G, Sharma Y et al. (2008) Exploring the limits of sequence
and structure in a variant betagamma-crystallin domain of the protein
absent in melanoma-1 (AIM1). J Mol Biol 381:509–18
Bahrami S, Cheng L, Wang M et al. (2007) Clonal relationships between
epidermotropic metastatic melanomas and their primary lesions: a loss of
heterozygosity and X-chromosome inactivation-based analysis. Mod
Pathol 20:821–7
Brouha B, Schustak J, Badge RM et al. (2003) Hot L1s account for the bulk of
retrotransposition in the human population. Proc Natl Acad Sci USA
100:5280–5
Chalitchagorn K, Shuangshoti S, Hourpai N et al. (2004) Distinctive pattern of
LINE-1 methylation level in normal tissues and the association with
carcinogenesis. Oncogene 23:8841–6
Cho NY, Kim BH, Choi M et al. (2007) Hypermethylation of CpG island loci
and hypomethylation of LINE-1 and Alu repeats in prostate adenocarci-
noma and their relationship to clinicopathological features. J Pathol
211:269–77
Coolen MW, Statham AL, Gardiner-Garden M et al. (2007) Genomic profiling
of CpG methylation and allelic specificity using quantitative high-
throughput mass spectrometry: critical evaluation and improvements.
Nucleic Acids Res 35:e119
Daskalos A, Nikolaidis G, Xinarianos G et al. (2009) Hypomethylation of
retrotransposable elements correlates with genomic instability in non-
small cell lung cancer. Int J Cancer 124:81–7
de Maat MF, Narita N, Benard A et al. (2010a) Development of sporadic
microsatellite instability in colorectal tumors involves hypermethylation
at methylated-in-tumor loci in adenoma. Am J Pathol 177:2347–56
de Maat MF, Umetani N, Sunami E et al. (2007a) Assessment of methylation
events during colorectal tumor progression by absolute quantitative
analysis of methylated alleles. Mol Cancer Res 5:461–71
de Maat MF, van de Velde CJ, Benard A et al. (2010b) Identification of a
quantitative MINT locus methylation profile predicting local regional
recurrence of rectal cancer. Clin Cancer Res 16:2811–8
de Maat MF, van de Velde CJ, Umetani N et al. (2007b) Epigenetic silencing
of cyclooxygenase-2 affects clinical outcome in gastric cancer. J Clin
Oncol 25:4887–94
de Maat MF, van de Velde CJ, van der Werff MP et al. (2008) Quantitative
analysis of methylation of genomic loci in early-stage rectal cancer
predicts distant recurrence. J Clin Oncol 26:2327–35
Eden A, Gaudet F, Waghmare A et al. (2003) Chromosomal instability and
tumors promoted by DNA hypomethylation. Science 300:455
Estecio MR, Gallegos J, Vallot C et al. (2010) Genome architecture marked by
retrotransposons modulates predisposition to DNA methylation in
cancer. Genome Res 20:1369–82
Estecio MR, Gharibyan V, Shen L et al. (2007) LINE-1 hypomethylation in
cancer is highly variable and inversely correlated with microsatellite
instability. PLoS ONE 2:e399
Fujiwara Y, Chi DD, Wang H et al. (1999) Plasma DNA microsatellites as
tumor-specific markers and indicators of tumor progression in melanoma
patients. Cancer Res 59:1567–71
Furuta J, Umebayashi Y, Miyamoto K et al. (2004) Promoter methylation
profiling of 30 genes in human malignant melanoma. Cancer Sci
95:962–8
Gaudet F, Hodgson JG, Eden A et al. (2003) Induction of tumors in mice by
genomic hypomethylation. Science 300:489–92
Haqq C, Nosrati M, Sudilovsky D et al. (2005) The gene expression signatures
of melanoma progression. Proc Natl Acad Sci USA 102:6092–7
Hoon DS, Spugnardi M, Kuo C et al. (2004) Profiling epigenetic inactivation
of tumor suppressor genes in tumors and plasma from cutaneous
melanoma patients. Oncogene 23:4014–22
Iqbal J, Kucuk C, Deleeuw RJ et al. (2009) Genomic analyses reveal global
functional alterations that promote tumor growth and novel tumor
suppressor genes in natural killer-cell malignancies. Leukemia
23:1139–51
Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128:683–92
1696 Journal of Investigative Dermatology (2012), Volume 132
S Hoshimoto et al.
LINE-1 and AIM1 Methylation in Melanoma
Koyanagi K, Mori T, O’Day SJ et al. (2006a) Association of circulating tumor
cells with serum tumor-related methylated DNA in peripheral blood of
melanoma patients. Cancer Res 66:6111–7
Koyanagi K, O’Day SJ, Boasberg P et al. (2010) Serial monitoring of
circulating tumor cells predicts outcome of induction biochemotherapy
plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res
16:2402–8
Koyanagi K, O’Day SJ, Gonzalez R et al. (2006b) Microphthalmia
transcription factor as a molecular marker for circulating tumor cell
detection in blood of melanoma patients. Clin Cancer Res 12:1137–43
Lander ES, Linton LM, Birren B et al. (2001) Initial sequencing and analysis of
the human genome. Nature 409:860–921
Lee HS, Kim BH, Cho NY et al. (2009) Prognostic implications of and
relationship between CpG island hypermethylation and repetitive DNA
hypomethylation in hepatocellular carcinoma. Clin Cancer Res
15:812–20
McShane LM, Altman DG, Sauerbrei W et al. (2005) Reporting recommenda-
tions for tumor marker prognostic studies. J Clin Oncol 23:9067–72
Minakami R, Kurose K, Etoh K et al. (1992) Identification of an internal cis-
element essential for the human L1 transcription and a nuclear factor(s)
binding to the element. Nucleic Acids Res 20:3139–45
Mirmohammadsadegh A, Marini A, Nambiar S et al. (2006) Epigenetic
silencing of the PTEN gene in melanoma. Cancer Res 66:6546–52
Mori T, O’Day SJ, Umetani N et al. (2005) Predictive utility of circulating
methylated DNA in serum of melanoma patients receiving biochem-
otherapy. J Clin Oncol 23:9351–8
Mungall AJ, Palmer SA, Sims SK et al. (2003) The DNA sequence and analysis
of human chromosome 6. Nature 425:805–11
Narita N, Tanemura A, Murali R et al. (2009) Functional RET G691S
polymorphism in cutaneous malignant melanoma. Oncogene
28:3058–68
Ogino S, Kawasaki T, Nosho K et al. (2008a) LINE-1 hypomethylation is
inversely associated with microsatellite instability and CpG island
methylator phenotype in colorectal cancer. Int J Cancer 122:2767–73
Ogino S, Nosho K, Kirkner GJ et al. (2008b) A cohort study of tumoral LINE-1
hypomethylation and prognosis in colon cancer. J Natl Cancer Inst
100:1734–8
Ostertag EM, Kazazian Jr HH (2001) Biology of mammalian L1 retro-
transposons. Annu Rev Genet 35:501–38
Ovchinnikov I, Rubin A, Swergold GD (2002) Tracing the LINEs of human
evolution. Proc Natl Acad Sci USA 99:10522–7
Patino WD, Susa J (2008) Epigenetics of cutaneous melanoma. Adv Dermatol
24:59–70
Pattamadilok J, Huapai N, Rattanatanyong P et al. (2008) LINE-1 hypomethy-
lation level as a potential prognostic factor for epithelial ovarian cancer.
Int J Gynecol Cancer 18:711–7
Poage GM, Houseman EA, Christensen BC et al. (2011) Global hypomethyla-
tion identifies loci targeted for hypermethylation in head and neck
cancer. Clin Cancer Res 17:3579–89
Radpour R, Haghighi MM, Fan AX et al. (2008) High-throughput hacking of
the methylation patterns in breast cancer by in vitro transcription and
thymidine-specific cleavage mass array on MALDI-TOF silico-chip. Mol
Cancer Res 6:1702–9
Ray ME, Wistow G, Su YA et al. (1997) AIM1, a novel non-lens member of the
betagamma-crystallin superfamily, is associated with the control of
tumorigenicity in human malignant melanoma. Proc Natl Acad Sci USA
94:3229–34
Schwarzenbach H, Hoon DS, Pantel K (2011) Cell-free nucleic acids as
biomarkers in cancer patients. Nat Rev Cancer 11:426–37
Scott AF, Schmeckpeper BJ, Abdelrazik M et al. (1987) Origin of the human
L1 elements: proposed progenitor genes deduced from a consensus DNA
sequence. Genomics 1:113–25
Sigalotti L, Fratta E, Bidoli E et al. (2011) Methylation levels of the ‘‘long
interspersed nucleotide element-1’’ repetitive sequences predict survival
of melanoma patients. J Transl Med 9:78
Stark M, Hayward N (2007) Genome-wide loss of heterozygosity and copy
number analysis in melanoma using high-density single-nucleotide
polymorphism arrays. Cancer Res 67:2632–42
Sunami E, de Maat M, Vu A et al. (2011) LINE-1 hypomethylation during
primary colon cancer progression. PLoS One 6:e18884
Sunami E, Vu AT, Nguyen SL et al. (2009) Analysis of methylated circulating
DNA in cancer patients’ blood. Methods Mol Biol 507:349–56
Takeuchi H, Morton DL, Kuo C et al. (2004) Prognostic significance of
molecular upstaging of paraffin-embedded sentinel lymph nodes in
melanoma patients. J Clin Oncol 22:2671–80
Tanemura A, Terando AM, Sim MS et al. (2009) CpG island methylator
phenotype predicts progression of malignant melanoma. Clin Cancer Res
15:1801–7
Tellez CS, Shen L, Estecio MR et al. (2009) CpG island methylation profiling
in human melanoma cell lines. Melanoma Res 19:146–55
Trent JM, Stanbridge EJ, McBride HL et al. (1990) Tumorigenicity in human
melanoma cell lines controlled by introduction of human chromosome
6. Science 247:568–71
Umetani N, de Maat MF, Mori T et al. (2005) Synthesis of universal
unmethylated control DNA by nested whole genome amplification with
phi29 DNA polymerase. Biochem Biophys Res Commun 329:219–23
Umetani N, Kim J, Hiramatsu S et al. (2006) Increased integrity of free
circulating DNA in sera of patients with colorectal or periampullary
cancer: direct quantitative PCR for ALU repeats. Clin Chem 52:1062–9
van Hoesel AQ, van de Velde CJ, Kuppen PJ et al. (2011) Primary tumor
classification according to methylation pattern is prognostic in patients
with early stage ER-negative breast cancer. Breast Cancer Res Treat
131:859–69
Worm J, Christensen C, Gronbaek K et al. (2004) Genetic and epigenetic
alterations of the APC gene in malignant melanoma. Oncogene
23:5215–26
Yang AS, Estecio MR, Doshi K et al. (2004) A simple method for estimating
global DNA methylation using bisulfite PCR of repetitive DNA elements.
Nucleic Acids Res 32:e38
Yoshimura T, Nagahara M, Kuo C et al. (2011) Lymphovascular invasion of
colorectal cancer is correlated to SPARC expression in the tumor stromal
microenvironment. Epigenetics 6:1001–11
www.jidonline.org 1697
S Hoshimoto et al.
LINE-1 and AIM1 Methylation in Melanoma
